Use of epidermal growth factor depleting agents in the treatment of the chronic obstructive pulmonary disease

The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chron...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PINO ALFONSO, PEDRO PABLO, HERNANDEZ REYES, JENYSBEL DE LA CARIDAD, MACIAS ABRAHAM, AMPARO EMILIA, LEON MONZON, KALET, SANTOS MORALES, ORESTES, SAAVEDRA HERNANDEZ, DANAY, LEE, KELVIN, CROMBET RAMOS, TANIA, REID, MARY, NENINGER VINAGERAS, ELIA
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chronic obstructive pulmonary disease. These agents can be vaccine compositions comprising as active principle the conjugate between recombinant human EGF and a carrier protein.